Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
Medical device company Avinger (NASDAQ: AVGR) has announced that it has received clearance from the US Food and Drug Administration (FDA) for its Ocelaris next-generation image-guided total occlusion crossing system.
The catheter-based system will be branded as TIGEREYE and provides real-time imaging from inside the vessel during a CTO-crossing procedure.
“We are excited to receive U.S. pre-marketing clearance for TIGEREYE, which we believe will be a significant growth driver for our CTO-crossing business,” said Jeff Soinski, Avinger's President and CEO.
The company believes it is a significant advancement for patients with chronic total occlusions and provides Avinger with a market growth opportunity as chronic total occlusions present a technical challenge to physicians treating peripheral artery disease.
AVGR Share Price…
The news has sent Avinger's share price racing higher. It is currently trading at $0.52 per share premarket, up 25%.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .